Coherus BioSciences Inc (CHRS)
0.7151
+0.05
(+6.73%)
USD |
NASDAQ |
Nov 05, 10:22
Coherus BioSciences Gross Profit Margin (Quarterly): 56.34% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 56.34% |
| March 31, 2024 | 55.12% |
| December 31, 2023 | 7.60% |
| September 30, 2023 | 56.14% |
| June 30, 2023 | 57.68% |
| March 31, 2023 | 47.98% |
| December 31, 2022 | 68.68% |
| September 30, 2022 | 22.43% |
| June 30, 2022 | 81.25% |
| March 31, 2022 | 84.41% |
| December 31, 2021 | 83.50% |
| Date | Value |
|---|---|
| September 30, 2021 | 74.21% |
| June 30, 2021 | 80.95% |
| March 31, 2021 | 90.95% |
| December 31, 2020 | 89.43% |
| September 30, 2020 | 92.07% |
| June 30, 2020 | 92.53% |
| March 31, 2020 | 94.10% |
| December 31, 2019 | 93.70% |
| September 30, 2019 | 94.23% |
| June 30, 2019 | 99.28% |
| March 31, 2019 | 94.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
7.60%
Minimum
Dec 2023
94.10%
Maximum
Mar 2020
69.95%
Average
80.95%
Median
Jun 2021
Gross Profit Margin (Quarterly) Benchmarks
| Repligen Corp | 49.82% |
| Evoke Pharma Inc | 98.37% |
| Personalis Inc | 35.59% |
| Maravai LifeSciences Holdings Inc | 47.86% |
| Tempus AI Inc | 45.50% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -4.70% |
| Return on Invested Capital | -9.85% |
| Profit Margin (Quarterly) | -19.88% |
| Operating Margin (Quarterly) | -31.56% |
| Return on Net Operating Assets | -7.86% |